The purpose of the report is to illustrate the state of the market of Erythropoietin Drugs, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.
Browse here for full report with Toc: https://www.credenceresearch.com/report/erythropoietin-drugs-market
According to the Centers for Disease Control and Prevention (CDC), around 5.5 Mn ambulatory care patients suffer from anemia due to a nutritional deficiency, while chronic disease is the second most prevalent cause. Even though anemia is a common symptom in chronic disease, it still goes underdiagnosed and undertreated, especially in chronic kidney disease (CKD) patients not undergoing dialysis anemia is undertreated. In U.S., around 20 Mn people suffer from CKD, out of which 2-4 million have anemia. Anemia increases substantial economic burden and also affects quality of life. Rising incidence of CKD, cancer and HIV is the major factor fuelling the demand of erythropoietin drugs. Advancement in recombinant DNA technology has led to introduction of different forms of drugs such as epoetin-beta, darbepoetin-alfa and others. Biologics currently dominate the erythropoietin drugs market; but the entry of novel drugs with biosimilar formulations with better efficacy and cost effectiveness would present lucrative opportunities. Biosimilars would be a fast growing market, especially in developing countries in Asia Pacific and Middle East & Africa, due to low cost therapeutics and enhanced efficacy.
Key players in the global erythropoietin drugs market are Amgen, Inc., Biocon Limited, Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffman-La Roche Ltd., Hospira, Inc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Inc., LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and others.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Erythropoietin Drugs buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Erythropoietin Drugs contains:
Analysis and forecast of Erythropoietin Drugs market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Erythropoietin Drugs market;
Assessment and forecast of Erythropoietin Drugs market development;
Financial and business profiles of the leading companies in the Erythropoietin Drugs industry.
Also you can request us for sample in PDF with depth details and graph: https://www.credenceresearch.com/sample-request/58548
– Up to date working Erythropoietin Drugs data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Erythropoietin Drugs for the period 2018 to 2026
– Planned Erythropoietin Drugs additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Erythropoietin Drugs projects by region, key countries, and companies
– Details of major planned Erythropoietin Drugs projects in the world up to 2026
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290